DailyBubble News
DailyBubble News

DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing

DaVita HealthCare (DVA) closed at $137.92 in the latest trading session, showing a 0.39% increase from the previous day. This performance surpassed the S&P 500’s daily gain of 0.07%, while the Dow experienced a loss of 0.13% and the Nasdaq saw a 0.14% increase.

Over the past month, DaVita HealthCare’s shares have declined by 2.97%, underperforming both the Medical sector’s loss of 1.99% and the S&P 500’s gain of 4.34%.

Investors are eagerly anticipating DaVita HealthCare’s upcoming earnings report, where the company is expected to post earnings of $2.47 per share, representing a year-over-year growth of 18.75%. Revenue is projected to reach $3.16 billion, up 5.43% from the same quarter last year.

For the full fiscal year, Zacks Consensus Estimates forecast earnings of $9.62 per share and revenue of $12.74 billion, reflecting changes of 13.58% and 4.97%, respectively, from the previous year.

Analyst estimates for DaVita HealthCare have an impact on stock performance, with positive revisions indicating confidence in the company’s future prospects. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), has historically outperformed expectations, with top-ranked stocks delivering an average annual return of 25% since 1988. Presently, DaVita HealthCare holds a Zacks Rank of #2 (Buy).

In terms of valuation, DaVita HealthCare currently trades at a Forward P/E ratio of 14.27, lower than the industry average of 22.5. The company also has a PEG ratio of 1.05, indicating a favorable earnings growth trajectory compared to the industry average of 2.

The Medical – Outpatient and Home Healthcare industry, to which DaVita HealthCare belongs, is ranked 52 out of over 250 industries, placing it in the top 21%. Industries with higher Zacks Industry Rank tend to outperform those with lower ranks.

Monitoring stock-influencing metrics on Zacks.com can provide valuable insights for investors in the upcoming trading sessions.

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x